Guidance and quality standards Awaiting development
Showing 21 to 25 of 25
| Title | Type |
|---|---|
| Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122] | Technology appraisal guidance |
| Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161] | Technology appraisal guidance |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158] | Technology appraisal guidance |
| Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382] | Technology appraisal guidance |